Gene Therapy for the Cardiomyopathy of Friedreich’s Ataxia
The purpose of this study is to test the safety of the study drug, which is an adeno-associated virus serotype rh10 gene transfer vector (AAVrh.10hFXN), and see what effects it has to treat the cardiomyopathy associated with Friedreich’s ataxia (FA).The study drug, AAVrh.10hFXN, is a gene transfer vector which uses an adeno-associated virus serotype rh.10 as a vehicle to deliver the FXN gene into heart cells. It is hoped that the study drug will help produce the normal amount of frataxin, and thus return the function of your heart cells and limit the effects of the cardiac disease.
ClinicalTrials.gov Link: clinicaltrials.gov/ct2/show/NCT05302271
About the Study
Eligible Ataxia Types
Friedreich’s Ataxia
Type of Study
Interventional Trial
Clinical Trial Phase
Phase 1
Age Range
18+
Study Start Date
03/21/2022
Estimated Completion Date
12/31/2028
IRB Approval #
20-01021274
Location(s)
Weill Cornell Medicine/NHLBI
Department of Genetic Medicine
1305 York Ave, 13th Floor
New York, NY
Contact Information
Niamh Savage
nis2049@med.cornell.edu
646-962-5527
What does participation in the study entail?
You will be asked to come back to WCM at days 1-4, 7, 10, and 14 after the drug infusion; 1, 3, 6 and 12 months following the infusion. After you complete the 12-month on-site visit, you will have an additional assessment at WCM in year 2 at 3, 6, 9 and 12 months, and years 3-5 once yearly.
What are the potential benefits for participants?
It is hoped that the study drug will help produce the normal amount of frataxin, and thus return the function of your heart cells and limit the effects of the cardiac disease.
What are the potential risks for participants?
The risks will be discussed with you by the study physician.
Is there financial compensation?
No.
Is there travel reimbursement?
Yes. At cost.
Who is eligible?
Patients who have been diagnosed with Friedreich’s Ataxia.
Additional Information or Resources
View Other Research Opportunities
Further Development and Validation of the Cerebellar Neuropsychiatric Rating Scale (CNRS)
There are many scales that assess the disruption of drive, motivation, mood, impulsivity, anxiety,and social cognition, in patients with psychiatric illness. However, no single scale covers theissues that we have Read More…
Clinical Care of Ataxia Patients
The goal of this study is to better understand the clinical practices of providers caring for patients with hereditary ataxias. This includes geographic estimates of patient prevalence and prescription habits. Read More…
The role of the cerebellum in movement and cognition
The aim of this study is to characterize how Ataxia impacts motor control and certain aspects of cognition (such as language and decision making). Link to Enroll: http://ivrylab.berkeley.edu/participate.html About the Read More…
